Physician profile
Neggy Rismanchi
NPI 1669759148
$4,779.82
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $866 · 2021: $575 · 2022: $1,039 · 2023: $459 · 2024: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $962.63 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $822.86 | 2019-2022 | |
| Greenwich Biosciences, INC. | $365.81 | 2019-2020 | |
| Sk Life Science, INC. | $331.15 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $323.58 | 2022-2024 | |
| Neuropace, INC. | $319.68 | 2019-2023 | |
| Ucb, INC. | $248.22 | 2021-2024 | Briviact |
| Eisai INC. | $237.47 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $227.44 | 2019 | |
| Immedica Pharma US, INC. | $163.02 | 2023-2024 | |
| Neurelis, INC. | $158.75 | 2020-2024 | Valtoco |
| Aquestive Therapeutics, INC. | $147.18 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $65.84 | 2023-2024 | Fycompa |
| Zogenix INC. | $62.21 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $56.55 | 2022-2023 | Eprontia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $55.00 | 2024 | Daybue |
| Mallinckrodt Hospital Products INC. | $50.24 | 2020 | |
| Csl Behring | $43.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.94 | 2020 | |
| Upsher-Smith Laboratories LLC | $21.60 | 2019 | |
| Sumitomo Pharma America, INC. | $21.11 | 2023 | Aptiom |
| Ptc Therapeutics, INC. | $18.55 | 2020 | |
| Biomarin Pharmaceutical INC. | $18.24 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.64 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.48 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neggy Rismanchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.